AstraZeneca Pharma shares up on CDSCO nod for cancer drug Lynparza
This approval establishes the use of Olaparib in combination with Durvalumab as a maintenance treatment for adult patients with advanced or recurrent endometrial cancer, said AstraZeneca Pharma
AstraZeneca's Lynparza: A New Hope in Cancer Treatment
AstraZeneca Pharma India has gained approval from India's drug regulator to import cancer treatment drug Lynparza for sale. The tablets are for use in combination therapy for patients with specific types of endometrial cancer.
AstraZeneca Pharma gets CSDCO nod to import anti-cancer drug Lynparza
In a regulatory filing, the company said it has received permission from the Central Drugs Standard Control Organisation (CSDCO), Directorate General of Health Services, Government of India, to import for sale and distribution of Olaparib film-coated Tablets 100 mg and 150 mg (Lynparza).
AstraZeneca Pharma gets nod for sale, distribution of cancer drug Lynparza
The Central Drugs Standard Control Organisation granted approval for the drug's use in combination with Durvalumab for the maintenance treatment of advanced or recurrent endometrial cancer in adults
AstraZeneca Pharma India Gets Approval To Import And Distribute Lynparza Cancer Drug
Olaparib in combination with Durvalumab is indicated for the maintenance treatment of adult patients with advanced or recurrent endometrial cancer whose disease has not progressed on first-line treatment with Durvalumab in combination with platinum-based chemotherapy,
AstraZeneca Pharma gains CDSCO approval to import cancer drug Lynparza
AstraZeneca Pharma India has received approval from the CDSCO for Olaparib film-coated tablets, set to launch in India for treating advanced endometrial cancer.
Scientists can predict how long prostate cancer patients will respond to olaparib
Scientists have worked out a way of predicting how long a prostate cancer patient will continue to respond to the PARP ...
Oncology Nurse Advisor8d
Olaparib May Be Option for Certain Patients With Biochemically Recurrent Prostate Cancer
Olaparib monotherapy may be a treatment option for some patients with high-risk biochemically recurrent prostate cancer, according to researchers.
Equity Bulls2d
AstraZeneca Pharma India Ltd receives permission for Olaparib film-coated tablets
AstraZeneca Pharma India Limited has received permission to import for sale and distribution in Form CT-20 from the CDSCO, ...
Hosted on MSN6mon
DCGI orders withdrawal of Olaparib for select cancer patients over safety concerns
New Delhi: The Drug Controller General of India (DCGI), Rajeev Raghuvanshi, has directed state authorities to withdraw AstraZeneca’s Olaparib Tablets, 100mg and 150mg, due to potential adverse ...
BBC1y
Olaparib: Drug to treat inherited cancers offered on NHS in England and Wales
The drug olaparib is designed to treat specific cancers linked to faulty versions of genes known as BRCAs. Around 500 men with advanced prostate cancer and 300 women with HER2-negative early ...
Medindia21d
Olaparib - Indications, Dosage, Side Effects and Precautions
Get detailed information on Olaparib, including pronunciation, uses, dosage guidelines, indications, and instructions on how and when to take it and when to avoid it. The updated prescription ...